Cboe UK GBp

Hikma Pharmaceuticals PLC (HIKL.XC)

Compare
2,292.00
+8.00
+(0.35%)
At close: January 31 at 4:29:55 PM GMT
Loading Chart for HIKL.XC
DELL
  • Previous Close 2,284.00
  • Open 2,256.00
  • Bid 2,290.00 x --
  • Ask 2,292.00 x --
  • Day's Range 2,256.00 - 2,295.00
  • 52 Week Range 1,760.50 - 2,295.00
  • Volume 54,631
  • Avg. Volume 69,299
  • Market Cap (intraday) 5.086B
  • Beta (5Y Monthly) 0.44
  • PE Ratio (TTM) 3,321.74
  • EPS (TTM) 0.69
  • Earnings Date Feb 26, 2025
  • Forward Dividend & Yield 0.62 (2.69%)
  • Ex-Dividend Date Aug 15, 2024
  • 1y Target Est --

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.

www.hikma.com

9,100

Full Time Employees

December 31

Fiscal Year Ends

Recent News: HIKL.XC

View More

Performance Overview: HIKL.XC

Trailing total returns as of 1/31/2025, which may include dividends or other distributions. Benchmark is

.

YTD Return

HIKL.XC
15.52%
FTSE 100
6.81%

1-Year Return

HIKL.XC
24.27%
FTSE 100
13.14%

3-Year Return

HIKL.XC
21.39%
FTSE 100
16.18%

5-Year Return

HIKL.XC
41.05%
FTSE 100
17.50%

Compare To: HIKL.XC

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: HIKL.XC

View More

Valuation Measures

Annual
As of 1/31/2025
  • Market Cap

    5.09B

  • Enterprise Value

    5.86B

  • Trailing P/E

    33.50

  • Forward P/E

    12.58

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    2.20

  • Price/Book (mrq)

    2.87

  • Enterprise Value/Revenue

    2.53

  • Enterprise Value/EBITDA

    13.19

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    9.45%

  • Return on Assets (ttm)

    9.40%

  • Return on Equity (ttm)

    12.88%

  • Revenue (ttm)

    3.02B

  • Net Income Avi to Common (ttm)

    285M

  • Diluted EPS (ttm)

    0.69

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    260M

  • Total Debt/Equity (mrq)

    55.48%

  • Levered Free Cash Flow (ttm)

    410.38M

Research Analysis: HIKL.XC

View More

Company Insights: HIKL.XC

Research Reports: HIKL.XC

View More

People Also Watch